PolymarketCheck availabilityNo KYCVerified resolution dataWell calibratedData quality warningNo live quotes
Data as of Oct 5, 2026, 9:30 PM UTC · policy pm-quality-4
Current implied probability
June 30, 83%
June 30, 83%Market quality
≤49 / 100
Low quality24h Volume
—
Liquidity
$7.6K
Medium liquidityBid / Ask
82.0% / 83.0%
Spread
1.0 pt
Tight spreadComments
0
Market data
Updated 13 minutes ago
Aug 19, 26, 6:47 PM UTCJul 1, 27, 3:59 AM UTC
Trends
Venue terms
Source: Polymarket
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Minimum order (shares):
- 5
- Tick size:
- 1 percentage points
- Fees:
- Yes
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRules
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.